Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin Combined With NHA Versus Single NHA in Metastatic Castrate-resistant Prostate Cancer
NCT07310433Phase 2Recruiting
- Sponsor
- Yungjin Pharmaceutical
- Start
- May 2026
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Yungjin Pharmaceutical. Started May 2026; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07310433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07310433.